PIK3CA and breast carcinoma: According to a clinical study published on Breast Cancer in 2021, compared to the TCGA datasets, which mainly consist of data from patients with breast cancer in western countries, the prevalence of PIK3CA mutation in patients with breast cancer in China is higher (45.6% vs. 34.7%, p < 0.001).